FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

ashington,	D.C. 20549	

OMB APP	ROVAL
OMB Number	3235_028

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Estimated average burden hours per response: 0.5

					or	Sect	tion 30(I	n) of the	e Inv	vestmer	nt Co	mpany Act	of 194	10						
1. Name and Address of Reporting Person* Landry Robert E				RI	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]								(Ch	eck all appli Directo	cable)	ng Person(s) to Is 10% O Other (
(Last)	ast) (First) (Middle) 77 OLD SAW MILL RIVER ROAD				3. Date of Earliest Transaction (Month/Day/Year) 01/12/2024										helow)	EVP Fin	nance	below)		
(Street)	ΓOWN	NY	10591		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		(State)	(Zip)		Rule 10b5-1(c) Transaction Indication															
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																				
		Tab	le I - No	n-Deriv	vative	e Se	ecuriti	ies A	cqu	uired,	Dis	posed o	of, or	Ber	neficial	ly Owne	d			
Dai			Date	(Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		, ;	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				Benefic Owned	es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									-	Code	v	Amount	(A (E	() or ()	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock 0				01/12	/2024					M		800		A	\$378.9	23	3,406		D	
Common Stock			01/12	/2024	2024				F		568		D	\$928.1	8 22	22,838		D		
Common Stock														2	270		I	By 401(k) Plan		
			Table II -									osed of converti				Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		e (Month/Day/Year)	3A. Deen Executio if any (Month/E	n Date, Trans Code			n of		Ex	6. Date Exercisi Expiration Date (Month/Day/Yea		•	7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Ownersi Form: Direct (Dor Indire (I) (Instr.	Ownership	Beneficial Ownershi (Instr. 4)
					Code	v	(A)	(D)	Dat Exc	ate ercisabl		Expiration Date	Title		Amount or Number of Shares					
Non- Qualified Stock Option (right to	\$378.98	01/12/2024			M			800		(1)	1	12/12/2027	Comr		800	\$0.0	14,68′	7	D	

Explanation of Responses:

1. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Robert E. Landry 01/17/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.